{"name": "PharmAbcine",
 "permalink": "pharmabcine",
 "crunchbase_url": "http://www.crunchbase.com/company/pharmabcine",
 "homepage_url": "http://www.pharmabcine.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "+82-42-863-2017~9",
 "description": "biotechnology company",
 "created_at": "Tue Sep 29 09:30:26 UTC 2009",
 "updated_at": "Tue Sep 29 09:37:57 UTC 2009",
 "overview": "\u003Cp\u003EPharmAbcine is a specialized biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases. Our mission is to develop a first-in-class and best-in-class mAb for those target diseases.\u003C/p\u003E\n\n\u003Cp\u003EPharmAbcine\u0026#8217;s business is mainly focused on out-licensing of candidate therapeutics and clinical application. \nFor this purpose, we builds competitive pipelines \u0026amp; drug discovery platform by in-house approach. When necessary, we consider extending strategic partnership for win-win business model. \u003C/p\u003E\n\n\u003Cp\u003EOur management team has expertise in all aspects of therapeutic antibody discovery and development, including marketing and we are also supported by world-class scientific advisors who are thought leaders in biology and medicine.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       35],
      "assets/images/resized/0006/1120/61120v1-max-150x150.png"],
     [[182,
       43],
      "assets/images/resized/0006/1120/61120v1-max-250x250.png"],
     [[182,
       43],
      "assets/images/resized/0006/1120/61120v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$6M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.bio-medicine.org/biology-technology-1/PharmAbcine-Closes-USD--246-Million-Series-A-Financing-14102-1/",
    "source_description": "PharmAbcine Closes USD $6 Million Series A Financing",
    "raised_amount": 6000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 9,
    "funded_day": 16,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Novartis Venture Fund",
         "permalink": "novartis-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               70],
              "assets/images/resized/0005/9083/59083v2-max-150x150.png"],
             [[250,
               117],
              "assets/images/resized/0005/9083/59083v2-max-250x250.png"],
             [[318,
               150],
              "assets/images/resized/0005/9083/59083v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "OrbiMed Advisors",
         "permalink": "orbimed-advisors",
         "image":
          {"available_sizes":
            [[[150,
               42],
              "assets/images/resized/0005/0248/50248v1-max-150x150.png"],
             [[203,
               58],
              "assets/images/resized/0005/0248/50248v1-max-250x250.png"],
             [[203,
               58],
              "assets/images/resized/0005/0248/50248v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Tong Yang Venture Capital",
         "permalink": "tong-yang-venture-capital",
         "image":
          {"available_sizes":
            [[[140,
               34],
              "assets/images/resized/0005/8439/58439v1-max-150x150.png"],
             [[140,
               34],
              "assets/images/resized/0005/8439/58439v1-max-250x250.png"],
             [[140,
               34],
              "assets/images/resized/0005/8439/58439v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company":
        {"name": "Green Cross",
         "permalink": "green-cross",
         "image":
          {"available_sizes":
            [[[150,
               52],
              "assets/images/resized/0006/1122/61122v1-max-150x150.jpg"],
             [[182,
               64],
              "assets/images/resized/0006/1122/61122v1-max-250x250.jpg"],
             [[182,
               64],
              "assets/images/resized/0006/1122/61122v1-max-450x450.jpg"]],
           "attribution": null}},
       "financial_org": null,
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "HQ",
    "address1": "Daejeon BioventureTown",
    "address2": "Jeonmin-Dong, Yuseong-Gu",
    "zip_code": "461-8",
    "city": "Daejeon",
    "state_code": null,
    "country_code": "KOR",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        117],
       "assets/images/resized/0006/1121/61121v1-max-150x150.jpg"],
      [[250,
        196],
       "assets/images/resized/0006/1121/61121v1-max-250x250.jpg"],
      [[450,
        353],
       "assets/images/resized/0006/1121/61121v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}